Publications
- Newest First
- Most Cited
- Most Discussed
Showing 1 - 100 results of 3,012 publications
2025
- Spatial transcriptomics in inflammatory skin diseases using GeoMx digital spatial profiling: a practical guide for applications in dermatologyCho C, Haddadi N, Kidacki M, Woodard G, Shakiba S, Yıldız-Altay Ü, Richmond J, Vesely M. Spatial transcriptomics in inflammatory skin diseases using GeoMx digital spatial profiling: a practical guide for applications in dermatology. JID Innovations 2025, 5: 100317. DOI: 10.1016/j.xjidi.2024.100317.
2024
- DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 TrialIyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, Choi W, Dinney C, Flaig T, Thompson I, Lerner S, McConkey D, Rosenberg J. DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. JCO Precision Oncology 2024, 8: e2400287. PMID: 39499893, DOI: 10.1200/po.24.00287.
- Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortiumHan J, Koh M, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Fernandez Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al-Mansour M, Ford J, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium. Blood Advances 2024 PMID: 39481087, DOI: 10.1182/bloodadvances.2024014674.
- Cutaneous fungal infections in the United States: A cross-sectional analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 2005–2016Spaulding S, Wride A, Slade M, Damsky W, Cohen J. Cutaneous fungal infections in the United States: A cross-sectional analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 2005–2016. Journal Of The American Academy Of Dermatology 2024 PMID: 39486764, DOI: 10.1016/j.jaad.2024.10.035.
- Don’t be so naïveHorsley V, Nassereddine A. Don’t be so naïve. ELife 2024, 13: e103292. PMID: 39453398, PMCID: PMC11509665, DOI: 10.7554/elife.103292.
- Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque PsoriasisArmstrong A, Soliman A, Gisondi P, Fang S, Patel M, Strober B. Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology And Therapy 2024, 1-11. PMID: 39453596, DOI: 10.1007/s13555-024-01293-y.
- Creating a Longitudinal, Clinical Dermatology Curriculum Based on Student Preferences and Gaps in Learning as Determined by a Needs AssessmentSwallow M, Ahmad M, Yu B, Saeed S, Johnston M, Nelson C, Perkins S. Creating a Longitudinal, Clinical Dermatology Curriculum Based on Student Preferences and Gaps in Learning as Determined by a Needs Assessment. Medical Science Educator 2024, 1-3. DOI: 10.1007/s40670-024-02199-2.
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up). British Journal Of Dermatology 2024, ljae404. PMID: 39438067, DOI: 10.1093/bjd/ljae404.
- Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder CancerSingh P, Ballas L, Sonpavde G, Chen R, Bangs R, Bauman B, Nagar H, Delacroix S, Lerner S, Efstathiou J. Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer. Bladder Cancer 2024, 10: 199-213. PMID: 39493817, PMCID: PMC11530036, DOI: 10.3233/blc-240036.
- Impact of Atopic Dermatitis (Eczema) and Its Treatment on the Risk of Adverse Events Following Total Knee ArthroplastySmith-Voudouris J, Dhodapkar M, Halperin S, Cohen J, Grauer J. Impact of Atopic Dermatitis (Eczema) and Its Treatment on the Risk of Adverse Events Following Total Knee Arthroplasty. JAAOS Global Research And Reviews 2024, 8: e23.00267. PMID: 39436712, PMCID: PMC11498930, DOI: 10.5435/jaaosglobal-d-23-00267.
- Bipolar disorder among individuals with atopic dermatitis: A case-control study in the All of Us Research ProgramWride A, Chen G, Fan R, Leasure A, Jones S, Levey D, Damsky W, Cohen J. Bipolar disorder among individuals with atopic dermatitis: A case-control study in the All of Us Research Program. Clinical And Experimental Dermatology 2024, llae451. PMID: 39425681, DOI: 10.1093/ced/llae451.
- Abstract PR-08: Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockadeCho C, Lopez F, Woodard G, Huang B, He J, Badri T, Kidacki M, Vesely M, Ng E, Wang G, Chen L. Abstract PR-08: Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade. Cancer Immunology Research 2024, 12: pr-08-pr-08. DOI: 10.1158/2326-6074.tumimm24-pr-08.
- Selective utilization of glucose metabolism guides mammalian gastrulationCao D, Bergmann J, Zhong L, Hemalatha A, Dingare C, Jensen T, Cox A, Greco V, Steventon B, Sozen B. Selective utilization of glucose metabolism guides mammalian gastrulation. Nature 2024, 634: 919-928. PMID: 39415005, PMCID: PMC11499262, DOI: 10.1038/s41586-024-08044-1.
- Ten Year Follow-up After Face Transplantation – a Single Center Retrospective Cohort StudyHuelsboemer L, Kauke-Navarro M, Boroumand S, Parikh N, Hosseini H, Yu C, Stögner V, Ko C, Perry B, Formica R, Hung P, Mahajan A, Azzi J, Murphy G, Pomahac B. Ten Year Follow-up After Face Transplantation – a Single Center Retrospective Cohort Study. American Journal Of Transplantation 2024 PMID: 39413877, DOI: 10.1016/j.ajt.2024.10.007.
- Association between atopic dermatitis and peripheral vascular disease: a cross-sectional study in the All of Us Research ProgramSpaulding S, Chen G, Craver A, Cohen J. Association between atopic dermatitis and peripheral vascular disease: a cross-sectional study in the All of Us Research Program. Clinical And Experimental Dermatology 2024, llae397. PMID: 39400111, DOI: 10.1093/ced/llae397.
- 7418 Xanthoma Disseminatum - A Rare cause of Diabetes InsipidusBalasubramanian P, Cohen J, Corbin Z, Panse G, Inzucchi S. 7418 Xanthoma Disseminatum - A Rare cause of Diabetes Insipidus. Journal Of The Endocrine Society 2024, 8: bvae163.1380. PMCID: PMC11454384, DOI: 10.1210/jendso/bvae163.1380.
- Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerLerner S, Tangen C, Svatek R, Daneshmand S, Pohar K, Skinner E, Schuckman A, Sagalowsky A, Smith N, Kamat A, Kassouf W, Plets M, Bangs R, Koppie T, Alva A, La Rosa F, Pal S, Kibel A, Canter D, Thompson I. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. New England Journal Of Medicine 2024, 391: 1206-1216. DOI: 10.1056/nejmoa2401497.
- Validation of the Delphi Consensus Diagnostic Criteria for Necrobiotic XanthogranulomaBassir F, Valido K, Maciejewski K, Damsky W, Nelson C. Validation of the Delphi Consensus Diagnostic Criteria for Necrobiotic Xanthogranuloma. JAMA Dermatology 2024, 160 PMID: 39356540, PMCID: PMC11447626, DOI: 10.1001/jamadermatol.2024.3198.
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia AreataKing B, Ko J, Kwon O, Vañó-Galván S, Piraccini B, Dutronc Y, Yu G, Liu C, Somani N, Ball S, Mesinkovska N. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata. JAMA Dermatology 2024, 160: 1075-1081. PMID: 39141364, PMCID: PMC11325239, DOI: 10.1001/jamadermatol.2024.2734.
- Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis.Daniele S, Galimberti F, Bunick C. Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis. Journal Of Drugs In Dermatology 2024, 23: 903-904. PMID: 39361690.
- Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis.Lain E, Bhatia N, Kircik L, Gold L, Harper J, Bunick C, Guenin E, Baldwin H, Feldman S, Rosso J. Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis. Journal Of Drugs In Dermatology 2024, 23: 873-881. PMID: 39361705, DOI: 10.36849/jdd.2024.8484.
- Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate CancerGoldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Hussain M, Quinn D, Dorff T, Lerner S, Thompson I, Agarwal N. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2437871. PMID: 39374015, DOI: 10.1001/jamanetworkopen.2024.37871.
- Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug ProductsKucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick C, Girardi M, Dabestani A, Light D. Evaluation of Benzene Presence and Formation in Benzoyl Peroxide Drug Products. Journal Of Investigative Dermatology 2024 PMID: 39384016, DOI: 10.1016/j.jid.2024.09.009.
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalisMesinkovska N, King B, Zhang X, Guttman‐Yassky E, Magnolo N, Sinclair R, Mizuashi M, Shapiro J, Peeva E, Banerjee A, Takiya L, Cox L, Wajsbrot D, Kerkmann U, Law E, Wolk R, Schaefer G. Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. The Journal Of Dermatology 2024, 51: 1414-1424. PMID: 39328096, DOI: 10.1111/1346-8138.17442.
- Perioral Hyaluronidase Injection for the Treatment of Microstomia in Systemic Sclerosis Patients: A Retrospective Cohort StudyElgash M, Kim S, Swallow M, Hinchcliff M, Suozzi K. Perioral Hyaluronidase Injection for the Treatment of Microstomia in Systemic Sclerosis Patients: A Retrospective Cohort Study. Journal Of The American Academy Of Dermatology 2024 PMID: 39307355, DOI: 10.1016/j.jaad.2024.09.019.
- IL-1β Induces Human Endothelial Surface Expression of IL-15 by Relieving let-7c-3p Suppression of Protein Translation.Mullan C, Summer L, Lopez-Giraldez F, Tobiasova Z, Manes T, Yasothan S, Song G, Jane-Wit D, Saltzman W, Pober J. IL-1β Induces Human Endothelial Surface Expression of IL-15 by Relieving let-7c-3p Suppression of Protein Translation. The Journal Of Immunology 2024, 213: 1338-1348. PMID: 39302113, PMCID: PMC11493510, DOI: 10.4049/jimmunol.2400331.
- Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analysesPeeva E, Yamaguchi Y, Ye Z, King B, Picardo M, Sloan A, Ezzedine K, Del Duca E, Estrada Y, Hassan‐Zahraee M, He W, Hyde C, Bar J, Facheris P, Guttman‐Yassky E. Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses. Experimental Dermatology 2024, 33: e15177. PMID: 39304339, DOI: 10.1111/exd.15177.
- Development of an Objective Structured Assessment of Technical Skills (OSATS) for SclerotherapyMa M, Zafar F, Goldman M, Munavalli G, Zimmet S, Nguyen T, Mishra V, Cartee T, Mann M, Hsu J, Silapunt S, Weiss R, Weiss M, Haq M, Ahmed A, Koza E, Shi V, Dave L, Yi M, Kang B, Cahn B, Bae Y, Kole L, Friedmann D, Chow M, Minkis K, Stücker M, Schlick C, Hoss E, Hu J, Kibbi N, Saikaly S, Greywal T, Hooper D, Vashi N, Boucher A, Ward K, Neuhaus I, Ghareeb E, Luke J, Karen J, Suggs A, Lucas J, Decker A, Brieva J, Yoo S, Suozzi K, Alam M. Development of an Objective Structured Assessment of Technical Skills (OSATS) for Sclerotherapy. Journal Of The American Academy Of Dermatology 2024 PMID: 39288871, DOI: 10.1016/j.jaad.2024.08.062.
- Abstract PR-01: Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibodyMartinez-Saucedo D, Quijano E, Ianniello Z, Rackear M, Liu Y, Hegan D, Chen H, Shan X, Tseng R, Yugawa D, Pinto-Medici N, Chowdhury S, Bindra R, Robert M, Saltzman W, Escobar-Hoyos L, Glazer P. Abstract PR-01: Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibody. Cancer Research 2024, 84: pr-01-pr-01. DOI: 10.1158/1538-7445.pancreatic24-pr-01.
- Retrospective analysis of nail findings in the National Registry for Ichthyosis and Related Disorders databaseCurtis K, Echeandia-Francis C, Falotico J, Luo A, Qiu Y, Grover C, Piraccini B, Choate K, Lipner S. Retrospective analysis of nail findings in the National Registry for Ichthyosis and Related Disorders database. Journal Of The American Academy Of Dermatology 2024 PMID: 39278313, DOI: 10.1016/j.jaad.2024.08.063.
- Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, jco2400767. PMID: 39255440, DOI: 10.1200/jco.24.00767.
- Real World Data on Efficacy and Safety of EPOCH in T-Cell LymphomaStraining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.
- Clinical and Histologic Variants of CD8+ Cutaneous T-Cell LymphomasSwallow M, Micevic G, Zhou A, Carlson K, Foss F, Girardi M. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas. Cancers 2024, 16: 3087. PMID: 39272944, PMCID: PMC11394026, DOI: 10.3390/cancers16173087.
- Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 TrialMaruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Inoue A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s229. DOI: 10.1016/s2152-2650(24)00908-x.
- TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 TrialMaruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Maruyama A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s523-s524. DOI: 10.1016/s2152-2650(24)01617-3.
- 50170 Cross-Sectional Survey of Hands-on Cosmetic and Laser Training in Dermatology ResidencyKang B, Minkis K, Suozzi K, Greywal T, Hoss E, Bolotin D, Kibbi N, Alam M. 50170 Cross-Sectional Survey of Hands-on Cosmetic and Laser Training in Dermatology Residency. Journal Of The American Academy Of Dermatology 2024, 91: ab170. DOI: 10.1016/j.jaad.2024.07.677.
- 285 Development of an electrochemiluminescence CFTR immunoassayBrowne J, Lee J, Peterec K, Garrison A, Bruscia E, Saltzman W, Egan M. 285 Development of an electrochemiluminescence CFTR immunoassay. Journal Of Cystic Fibrosis 2024, 23: s152. DOI: 10.1016/s1569-1993(24)01125-1.
- 264 Poly(amine-co-ester) nanoparticle delivery of CFTR mRNA shows restoration of CFTR activity in cystic fibrosis airway modelsGarrison A, Lee J, Browne J, Akhtar L, Peterec K, Suberi A, Eaton D, Ene M, Zhang X, Whang C, Oez H, Kizilirmak T, Bruscia E, Piotrowski-Daspit A, Saltzman W, Egan M. 264 Poly(amine-co-ester) nanoparticle delivery of CFTR mRNA shows restoration of CFTR activity in cystic fibrosis airway models. Journal Of Cystic Fibrosis 2024, 23: s140-s141. DOI: 10.1016/s1569-1993(24)01104-4.
- 295 Polymeric nanoparticles for in utero gene delivery in non-human primatesPiotrowski-Daspit A, Lynn A, Eaton D, Bracaglia L, Mortlock R, Tarantal A, Glazer P, Saltzman W. 295 Polymeric nanoparticles for in utero gene delivery in non-human primates. Journal Of Cystic Fibrosis 2024, 23: s157. DOI: 10.1016/s1569-1993(24)01135-4.
- 54712 Bipolar disorder among patients with atopic dermatitis: A case-control study in the All of Us research programWride M, Chen G, Fan R, Leasure A, Levey D, Damsky W, Cohen J. 54712 Bipolar disorder among patients with atopic dermatitis: A case-control study in the All of Us research program. Journal Of The American Academy Of Dermatology 2024, 91: ab147. DOI: 10.1016/j.jaad.2024.07.584.
- 53614 Stigma drives mental health issues in children and adolescents with vitiligoYang L, Rangel S, Griffith J, Chamlin S, Paller A, Hogeling M, Schoch J, FAAD, Rehmus W, Castelo-Soccio L, Antaya R. 53614 Stigma drives mental health issues in children and adolescents with vitiligo. Journal Of The American Academy Of Dermatology 2024, 91: ab317. DOI: 10.1016/j.jaad.2024.07.1260.
- 51523 The Phase 3 Vehicle-Controlled ASCEND Trial of Polyethylene Glycol Based Topical Isotretinoin (TMB-001 0.05% ointment) for Treatment of X-Linked and Autosomal Recessive Congenital Ichthyosis: Pharmacokinetic Results Compared with 80 mg Oral IsotretinoinBunick C, Huynh T, Jackson M, Lee L, Kempers S, Mendelsohn A, Eursken B, Ahson A, Raiz J, MC. Teng J. 51523 The Phase 3 Vehicle-Controlled ASCEND Trial of Polyethylene Glycol Based Topical Isotretinoin (TMB-001 0.05% ointment) for Treatment of X-Linked and Autosomal Recessive Congenital Ichthyosis: Pharmacokinetic Results Compared with 80 mg Oral Isotretinoin. Journal Of The American Academy Of Dermatology 2024, 91: ab332. DOI: 10.1016/j.jaad.2024.07.1321.
- 49169 Impact of secukinumab on high-sensitivity C-reactive protein and erythrocyte sedimentation rate: Post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 randomized trialsvan Straalen K, Bunick C, Lobach I, Uhlmann L, Passera A, Alarcon I, Wozniak M, Ravichandran S, Martinez A, da Costa A, Bechara F. 49169 Impact of secukinumab on high-sensitivity C-reactive protein and erythrocyte sedimentation rate: Post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 randomized trials. Journal Of The American Academy Of Dermatology 2024, 91: ab235. DOI: 10.1016/j.jaad.2024.07.932.
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 TrialsSenna M, King B, Mesinkovska N, Mostaghimi A, Hamilton C, Cassella J. 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials. Journal Of The American Academy Of Dermatology 2024, 91: ab39. DOI: 10.1016/j.jaad.2024.07.161.
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areataMostaghimi A, Augustin M, Harada K, Senna M, Dutronc Y, Yu G, Ball S, Murage M, Kolodsick J, King B. 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata. Journal Of The American Academy Of Dermatology 2024, 91: ab15. DOI: 10.1016/j.jaad.2024.07.071.
- 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2Senna M, Mostaghimi A, Ohyama M, Sinclair R, Chiasserini C, Dutronc Y, Somani N, Yu G, Kolodsick J, King B. 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2. Journal Of The American Academy Of Dermatology 2024, 91: ab251. DOI: 10.1016/j.jaad.2024.07.996.
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical TrialsKing B, Mostaghimi A, Ohyama M, Senna M, Chiasserini C, Dutronc Y, Liu C, Yu G, Murage M, Sinclair R. 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials. Journal Of The American Academy Of Dermatology 2024, 91: ab69. DOI: 10.1016/j.jaad.2024.07.282.
- 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinibKing B, Senna M, Ohyama M, Dutronc Y, Lu N, Chiasserini C, Somani N, Piraccini B. 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinib. Journal Of The American Academy Of Dermatology 2024, 91: ab340. DOI: 10.1016/j.jaad.2024.07.1353.
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia AreataKing B, Mesinkovska N, Mostaghimi A, Hamilton C, Cassella J. 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata. Journal Of The American Academy Of Dermatology 2024, 91: ab281. DOI: 10.1016/j.jaad.2024.07.1117.
- 54029 Pooled Patient-Reported Outcomes from the Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia AreataMesinkovska N, King B, Mostaghimi A, Hamilton C, Cassella J. 54029 Pooled Patient-Reported Outcomes from the Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata. Journal Of The American Academy Of Dermatology 2024, 91: ab71. DOI: 10.1016/j.jaad.2024.07.289.
- 51436 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 2.3 years and up to 4 Years of ExposureKing B, Mostaghimi A, Shimomura Y, Piraccini B, Blume-Peytavi U, Sontag A, Dutronc Y, Holzwarth K, Kolodsick J, Lu X, Sinclair R. 51436 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 2.3 years and up to 4 Years of Exposure. Journal Of The American Academy Of Dermatology 2024, 91: ab82. DOI: 10.1016/j.jaad.2024.07.336.
- 54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Langley R, Fiorentino D, Bagel J, Lafferty K, Skobelev E, Langholff W, Lebwohl M, Ho V, Strober B. 54131 Malignancy Rates in Patients With a History of Malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2024, 91: ab61. DOI: 10.1016/j.jaad.2024.07.252.
- 52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trialsGordon K, Thaçi D, Gooderham M, Okubo Y, Strober B, Peterson L, Deherder D, Pinto J, Gisondi P. 52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials. Journal Of The American Academy Of Dermatology 2024, 91: ab145. DOI: 10.1016/j.jaad.2024.07.577.
- 51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per Dermatology Life Quality Index scores: Data from the Effisayil 2 trialGottlieb A, Strober B, Kokolakis G, Merola J, Zheng M, Langley R, Tang M, Hofmann P, Thoma C, Warren R. 51856 Spesolimab rapidly improves quality of life in patients with generalized pustular psoriasis, as per Dermatology Life Quality Index scores: Data from the Effisayil 2 trial. Journal Of The American Academy Of Dermatology 2024, 91: ab316. DOI: 10.1016/j.jaad.2024.07.1256.
- 52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AASicco K, Soung J, Strober B, Irvine A, Wajsbrot D, Gromek K, Wolk R, Barnes D, Takiya L. 52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA. Journal Of The American Academy Of Dermatology 2024, 91: ab55. DOI: 10.1016/j.jaad.2024.07.228.
- 52284 Influence of Biological Sex on Clinical Manifestation in Moderate-to-Severe Atopic Dermatitis and on Dupilumab Treatment EffectivenessZink A, Beck L, Lebwohl M, Gooderham M, Strober B, Maul J, Pinter A, Johansson E, Chen Z, Hagen S, Bastian M. 52284 Influence of Biological Sex on Clinical Manifestation in Moderate-to-Severe Atopic Dermatitis and on Dupilumab Treatment Effectiveness. Journal Of The American Academy Of Dermatology 2024, 91: ab240. DOI: 10.1016/j.jaad.2024.07.952.
- 54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Strober B, Augustin M, Tada Y, Lafferty K, Skobelev E, Langholff W, Fakharzadeh S, Gniadecki R. 54148 Characteristics of Real-world Patients With Psoriasis Prescribed Guselkumab or Interleukin-17 Inhibitors: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2024, 91: ab152. DOI: 10.1016/j.jaad.2024.07.605.
- 50857 Treatment Discontinuation Patterns in Patients With Psoriasis Receiving Apremilast in North America: A Registry-Based AnalysisStrober B, Zhong Y, Varga S, Napoli A, Sima A, Beeghly A, Zhuo J. 50857 Treatment Discontinuation Patterns in Patients With Psoriasis Receiving Apremilast in North America: A Registry-Based Analysis. Journal Of The American Academy Of Dermatology 2024, 91: ab93. DOI: 10.1016/j.jaad.2024.07.377.
- 51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis RegistryArmstrong A, Ferris L, Callis-Duffin K, Sima A, Eckmann T, Beeghly A, Photowala H, Patel M, Garg V, Strober B. 51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2024, 91: ab59. DOI: 10.1016/j.jaad.2024.07.244.
- 54001 Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks: Subgroup Analysis by Baseline Demographics and Disease Characteristics From the LIMMitless TrialStrober B, Wu T, Photowala H, Chen M, Bachelez H. 54001 Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks: Subgroup Analysis by Baseline Demographics and Disease Characteristics From the LIMMitless Trial. Journal Of The American Academy Of Dermatology 2024, 91: ab37. DOI: 10.1016/j.jaad.2024.07.157.
- 52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trialsStrober B, Krueger J, Magnolo N, Vender R, Boehncke W, Hong H, Tilt N, Staelens F, Wiegratz S, Paul C. 52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials. Journal Of The American Academy Of Dermatology 2024, 91: ab142. DOI: 10.1016/j.jaad.2024.07.572.
- 51099 Real-world application of the International Psoriasis Council guidelines for prescribing systemic treatment to patients with psoriasis in North AmericaStrober B, Zhong Y, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. 51099 Real-world application of the International Psoriasis Council guidelines for prescribing systemic treatment to patients with psoriasis in North America. Journal Of The American Academy Of Dermatology 2024, 91: ab293. DOI: 10.1016/j.jaad.2024.07.1164.
- 51342 Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the Effisayil 2 and Effisayil ON trialsThaçi D, Morita A, Strober B, Torres T, Pinter A, Marzano A, Krueger J, Tang M, Hofmann P, Thoma C, Lebwohl M. 51342 Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the Effisayil 2 and Effisayil ON trials. Journal Of The American Academy Of Dermatology 2024, 91: ab46. DOI: 10.1016/j.jaad.2024.07.192.
- 51349 Spesolimab for the prevention of generalized pustular psoriasis (GPP) flares in White/Caucasian patients: Results from the randomized, placebo-controlled Effisayil 2 studyStrober B, Warren R, Gordon K, Langley R, Lebwohl M, Puig L, Tang M, Radic T, Hofmann P, Thoma C, Thaçi D. 51349 Spesolimab for the prevention of generalized pustular psoriasis (GPP) flares in White/Caucasian patients: Results from the randomized, placebo-controlled Effisayil 2 study. Journal Of The American Academy Of Dermatology 2024, 91: ab87. DOI: 10.1016/j.jaad.2024.07.354.
- 50668 Long-term Impact of Apremilast on Cardiometabolic Parameters and the Relationship of Cardiometabolic Changes With Psoriasis EfficacyStrober B, Crowley J, Langley R, Deignan C, Teng L, Zhou Z, Mehta N. 50668 Long-term Impact of Apremilast on Cardiometabolic Parameters and the Relationship of Cardiometabolic Changes With Psoriasis Efficacy. Journal Of The American Academy Of Dermatology 2024, 91: ab60. DOI: 10.1016/j.jaad.2024.07.245.
- P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.
- Post-Acute sequelae of COVID-19 in pediatric patients within the United States: A Scoping ReviewMiller C, Borre C, Green A, Funaro M, Oliveira C, Iwasaki A. Post-Acute sequelae of COVID-19 in pediatric patients within the United States: A Scoping Review. American Journal Of Medicine Open 2024, 100078. DOI: 10.1016/j.ajmo.2024.100078.
- 1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanomaWarner A, Smithy J, Los C, Kalvin H, Hasson N, Amaria R, Czapla J, Schollenberger M, furness A, Hassel J, Wermke M, Gallegos J, Lutzky J, Lipson E, Sullivan R, Kluger H, Panageas K, Klobuch S, Haanen J, Shoushtari A. 1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma. Annals Of Oncology 2024, 35: s730-s731. DOI: 10.1016/j.annonc.2024.08.1170.
- 1620P Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)Ingles S, Pinski J, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, Tangen C, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. 1620P Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216). Annals Of Oncology 2024, 35: s978. DOI: 10.1016/j.annonc.2024.08.1701.
- Collaborative management of specialty medications by a dermatologist and pharmacist: a retrospective cohort pilot studySpaulding S, Slade M, Tong K, Stroedecke N, Shin H, Cohen J. Collaborative management of specialty medications by a dermatologist and pharmacist: a retrospective cohort pilot study. International Journal Of Dermatology 2024, 63: e361-e363. PMID: 39212107, PMCID: PMC11490358, DOI: 10.1111/ijd.17462.
- Hepatitis C and its treatment in patients with psoriasis: a propensity-matched case-control studyZhu H, Shaw V, Cohen J. Hepatitis C and its treatment in patients with psoriasis: a propensity-matched case-control study. Archives Of Dermatological Research 2024, 316: 580. PMID: 39207533, DOI: 10.1007/s00403-024-03340-2.
- Risk of Developing Inflammatory Arthritis in Psoriasis Patients Initiating Treatment With Biologics: A Population Based AnalysisStrober B, Soliman A, Li C, Patel M, Unigwe I, Gisondi P. Risk of Developing Inflammatory Arthritis in Psoriasis Patients Initiating Treatment With Biologics: A Population Based Analysis. Journal Of The American Academy Of Dermatology 2024 PMID: 39197499, DOI: 10.1016/j.jaad.2024.06.106.
- Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancerTaylor J, Kamat A, O'Donnell M, Annapureddy D, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International 2024 PMID: 39183466, DOI: 10.1111/bju.16509.
- Statins Inhibit Cutaneous Squamous Cell Carcinoma CellsHACKETT A, COHEN A, RUTENBERG T, HODAK E, MOYAL L, ATZMONY L. Statins Inhibit Cutaneous Squamous Cell Carcinoma Cells. Acta Dermato Venereologica 2024, 104: 25097. PMID: 39185545, PMCID: PMC11367778, DOI: 10.2340/actadv.v104.25097.
- Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient SelectionLi R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024 PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.
- Cross-tissue organization of myeloid cells in scleroderma and related fibrotic diseasesOdell I. Cross-tissue organization of myeloid cells in scleroderma and related fibrotic diseases. Current Opinion In Rheumatology 2024, 36: 379-386. PMID: 39171604, PMCID: PMC11451931, DOI: 10.1097/bor.0000000000001047.
- Chemiexcitation in preventing macular degenerationBrash D, Gaillard E. Chemiexcitation in preventing macular degeneration. Frontiers In Photonics 2024, 5: 1451857. DOI: 10.3389/fphot.2024.1451857.
- Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correctionLi X, Liu T, Bacchiocchi A, Li M, Cheng W, Wittkop T, Mendez F, Wang Y, Tang P, Yao Q, Bosenberg M, Sznol M, Yan Q, Faham M, Weng L, Halaban R, Jin H, Hu Z. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. EMBO Molecular Medicine 2024, 16: 2188-2209. PMID: 39164471, PMCID: PMC11393307, DOI: 10.1038/s44321-024-00115-0.
- Alterations in the Skin Microbiome in Dermatologic Diseases and with External Exposures: CME Part 2MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. Alterations in the Skin Microbiome in Dermatologic Diseases and with External Exposures: CME Part 2. Journal Of The American Academy Of Dermatology 2024 PMID: 39173885, DOI: 10.1016/j.jaad.2024.07.1499.
- The Human Skin Microbiome in Health: CME Part 1MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. The Human Skin Microbiome in Health: CME Part 1. Journal Of The American Academy Of Dermatology 2024 PMID: 39168311, DOI: 10.1016/j.jaad.2024.07.1498.
- SRF SUMOylation modulates smooth muscle phenotypic switch and vascular remodelingXu Y, Zhang H, Chen Y, Pober J, Zhou M, Zhou J, Min W. SRF SUMOylation modulates smooth muscle phenotypic switch and vascular remodeling. Nature Communications 2024, 15: 6919. PMID: 39134547, PMCID: PMC11319592, DOI: 10.1038/s41467-024-51350-5.
- The human CD47 checkpoint is targeted by an immunosuppressive Aedes aegypti salivary factor to enhance arboviral skin infectivityMarin-Lopez A, Huck J, Esterly A, Azcutia V, Rosen C, Garcia-Milian R, Sefik E, Vidal-Pedrola G, Raduwan H, Chen T, Arora G, Halene S, Shaw A, Palm N, Flavell R, Parkos C, Thangamani S, Ring A, Fikrig E. The human CD47 checkpoint is targeted by an immunosuppressive Aedes aegypti salivary factor to enhance arboviral skin infectivity. Science Immunology 2024, 9: eadk9872. PMID: 39121194, DOI: 10.1126/sciimmunol.adk9872.
- Long COVID science, research and policyAl-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A, Topol E. Long COVID science, research and policy. Nature Medicine 2024, 30: 2148-2164. PMID: 39122965, DOI: 10.1038/s41591-024-03173-6.
- Geographical Trends in Psoriasis Injectable Biologic Prescriptions by Dermatologists Among Medicare BeneficiariesSun Q, Feng H, Cohen J. Geographical Trends in Psoriasis Injectable Biologic Prescriptions by Dermatologists Among Medicare Beneficiaries. Journal Of The American Academy Of Dermatology 2024 PMID: 39127130, DOI: 10.1016/j.jaad.2024.07.1490.
- Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by ClindamycinLomakin I, Devarkar S, Grada A, Bunick C. Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin. Journal Of Investigative Dermatology 2024, 144: 2553-2561.e3. PMID: 39122144, DOI: 10.1016/j.jid.2024.07.013.
- Enhanced intratumoral delivery of immunomodulator MPLA via hyperbranched polyglycerol-coated biodegradable nanoparticlesChang J, Shin K, Lewis J, Suh H, Lee J, Damsky W, Xu S, Bosenberg M, Saltzman W, Girardi M. Enhanced intratumoral delivery of immunomodulator MPLA via hyperbranched polyglycerol-coated biodegradable nanoparticles. Journal Of Investigative Dermatology 2024 PMID: 39122142, DOI: 10.1016/j.jid.2024.07.019.
- 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based studyBunick C, Grada A, Del Rosso J, Armstrong A, Yue E, Krueger W. 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study. British Journal Of Dermatology 2024, 191: ljae266.057. DOI: 10.1093/bjd/ljae266.057.
- 734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Eyerich K. 734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up). British Journal Of Dermatology 2024, 191: ljae266.107. DOI: 10.1093/bjd/ljae266.107.
- 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims dataVleugels R, Grada A, Yue E, Bunick C, Galimberti F, Krueger W. 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.055. DOI: 10.1093/bjd/ljae266.055.
- 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studiesPrajapati V, Bunick C, Eyerich K, Gold L, Galimberti F, Calimlim B, Teixeira H, Hu X, Yang Y, Sancho C, Grada A, Irvine A. 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. British Journal Of Dermatology 2024, 191: ljae266.070. DOI: 10.1093/bjd/ljae266.070.
- 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims dataLebwohl M, Yue E, Krueger W, Berman B, Bunick C, Schlesinger T, Grada A. 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.071. DOI: 10.1093/bjd/ljae266.071.
- 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP studySilverberg J, Calimlim B, Fuxench Z, Altman K, Bensimon A, Liu J, Bunick C. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study. British Journal Of Dermatology 2024, 191: ljae266.080. DOI: 10.1093/bjd/ljae266.080.
- 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitisBunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 191: ljae266.021. DOI: 10.1093/bjd/ljae266.021.
- 699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based studyMostaghimi A, Armstrong A, Grada A, Soliman A, Li C, C Bristow C, Lipiszko D, Silverberg J, Issa N, Bunick C. 699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study. British Journal Of Dermatology 2024, 191: ljae266.073. DOI: 10.1093/bjd/ljae266.073.
- Plasma collagen neoepitopes are associated with multiorgan disease in the ACCESS and GRADS sarcoidosis cohortsSand J, Jessen H, Leeming D, Yu S, Lee C, Hu B, Sun Y, Adams T, Pivarnik T, Liu A, Woo S, McGovern J, Fiorini V, Saber T, Higuero-Sevilla J, Gulati M, Kaminski N, Damsky W, Shaw A, Mohanty S, Goobie G, Zhang Y, Herzog E, Ryu C. Plasma collagen neoepitopes are associated with multiorgan disease in the ACCESS and GRADS sarcoidosis cohorts. Thorax 2024, thorax-2023-221095. PMID: 39117421, DOI: 10.1136/thorax-2023-221095.
- TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.
- GP100 expression is variable in intensity in melanomaMann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.
- Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutationGupta A, Barone C, Quijano E, Piotrowski-Daspit A, Perera J, Riccardi A, Jamali H, Turchick A, Zao W, Saltzman W, Glazer P, Egan M. Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation. Journal Of Cystic Fibrosis 2024 PMID: 39107154, DOI: 10.1016/j.jcf.2024.07.009.
- Development of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC)Kashima S, Gupta R, Moritz V, Sadak K, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. Development of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC). The Oncologist 2024, 29: s5-s6. PMCID: PMC11301923, DOI: 10.1093/oncolo/oyae181.008.
- Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disordersDaccache J, Park E, Junejo M, Abdelghaffar M, Hwang E, Mohanty C, Singh C, Wang G, Wheeler J, Shields B, Nelson C, Wang Y, Damsky W. Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disorders. Journal Of Allergy And Clinical Immunology 2024, 154: 1216-1231. PMID: 39098508, DOI: 10.1016/j.jaci.2024.07.021.